Nanoencapsulation of pomegranate bioactive compounds for XXXX chemoprevention.

@entity3978 @entity970 @entity0 @entity21112 @entity14956 @entity7050 @entity6398 @entity13983 @entity968
Pomegranate @entity6398 are potent antioxidants and chemopreventive agents but have low bioavailability and a short half-life. For example, @entity14956 (PU), the major @entity3978 in pomegranates, is not absorbed in its intact form but is hydrolyzed to @entity13983 (EA) moieties and rapidly metabolized into short-lived metabolites of EA. We hypothesized that encapsulation of pomegranate @entity6398 into biodegradable sustained release nanoparticles (NPs) may circumvent these limitations. We describe here the development, characterization, and bioactivity assessment of novel formulations of @entity7050 - @entity968 ( @entity7050 - @entity970 ) NPs loaded with pomegranate extract (PE) or individual @entity6398 such as PU or EA. Monodispersed, spherical 150-200 nm average diameter NPs were prepared by the double emulsion-solvent evaporation method. Uptake of @entity21112 -labeled NPs was evaluated in MCF-7 @entity0 cells over a 24-hour time course. Confocal fluorescent microscopy revealed that @entity7050 - @entity970 NPs were efficiently taken up, and the uptake reached the maximum at 24 hours. In addition, we examined the antiproliferative effects of PE-, PU-, and/or EA-loaded NPs in MCF-7 and Hs578T @entity0 cells. We found that PE, PU, and EA nanoprototypes had a 2- to 12-fold enhanced effect on cell growth inhibition compared to their free counterparts, while void NPs did not affect cell growth. PU-NPs were the most potent nanoprototype of pomegranates. Thus, PU may be the @entity3978 of choice for further chemoprevention studies with pomegranate nanoprototypes. These data demonstrate that nanotechnology-enabled delivery of pomegranate @entity6398 enhances their anticancer effects in @entity0 cells. Thus, pomegranate @entity6398 are promising agents for nanochemoprevention of @entity0 .
